Publications

Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell…

Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase 1 study patients with fgfr genomically activated advanced…

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient…

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I

The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Activity of Debio 1452 against Staphylococcus spp. collected in 2013 / 2014